Efficacy and tolerability of PTK787/ZK 222584 in a phase II study of post-transplant maintenance therapy in patients with multiple myeloma following high-dose chemotherapy and autologous stem cell transplant

Leukemia and Lymphoma

Volumn 51, Issue 8, 2010, Pages 1577-1579

  Vij, Ravi ^a   Ansstas, George ^a   Mosley, James C ^a   Bryant, George ^a   Hassan, Anjum ^a   Amador Ortiz, Catalina ^a   Procknow, Elizabeth ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; CD34 ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PARAPROTEIN; VATALANIB;

ADULT; AGED; ANGIOGENESIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW; BONE MARROW BIOPSY; CANCER CELL; CARDIOTOXICITY; CELL LINE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DOWN REGULATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; IC 50; IMMUNOHISTOCHEMISTRY; LETTER; MAINTENANCE THERAPY; MALE; MULTIPLE MYELOMA; NEUROTOXICITY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN PHOSPHORYLATION; STROMA CELL; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIPLE MYELOMA; PHTHALAZINES; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; PYRIDINES; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 77955433927     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.488709     Document Type: Letter

References (15)

1. Di Raimondo F, Azzaro MP, Palumbo G, et al. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica 2000;85:800-805.
2. Munshi N, Wilson CS, Penn J, et al. Angiogenesis in newly diagnosed multiple myeloma: poor prognosis with increased microvessel density in bone marrow biopsies. Blood 1998; 92(Suppl. 1): (Abstract 98).
3. Rajkumar SV, Leong T, Roche PC, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000;6:3111-3116.
4. Ribatti D, Vacca A, Nico B, et al. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer 1999;79:451-455.
5. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999;93:3064-3073.
6. Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001;15:1950-1961.
7. Dankbar B, Padro T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000;95:2630-2636.
8. Podar K, Tai YT, Davies FE, et al. Vascular endothelial growth factor (VEGF) triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001;98:428-435.
9. Podar K, Tai YT, Lin BK, et al. Vascular endothelial growth factor (VEGF)-induced migration of multiple myeloma cells is associated with b1-integrin and PI3-kinase-dependent PKCa activation. J Biol Chem 2002;277:7875-7881.
10. Kumar S, Gertz MA, Dispenzieri A, et al. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplant 2004;34:235-239.
11. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000;96:2240-2245.
12. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor induced responses and tumor growth after oral administration. Cancer Res 2000;60:2178-2189.
13. Lin B, Podar K, Gupta D, et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2002;62:5019-5026.
14. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998;102:1115-1123.
15. Vermeulen PB, Gasparini G, Fox SB, et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of valuation. Eur J Cancer 1996;32A:2474-2484.